The global therapeutic proteins for cardiovascular disorders treatment market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of cardiovascular diseases and rising awareness about the benefits of therapeutic proteins in treating these diseases.
The global therapeutic proteins for cardiovascular disorders treatment market by type includes monoclonal antibodies, peptides, and peptide fragments. Monoclonal antibodies are used in treating heart failure, myocardial infarction, arrhythmias, coronary artery disease and ischemic heart disease. Peptides are used in treating heart failure and myocardial infarction while peptide fragments are used in treating arrhythmias and coronary artery disease. The monoclonal antibodies segment accounted for the largest share of this market due to their wide range of applications across various types of cardiovascular disorders treatments such as heart failure, myocardial infarction etc, which makes them more popular among patients than other types such as peptides or peptide fragments that have limited applications across different types of treatments.
North America was estimated to account for the largest share (37%) followed by Europe (25%), Asia Pacific (21%), Latin America (8%) Middle East & Africa (6%). North America was estimated to account for the largest share due to its high prevalence rates coupled with high healthcare expenditure per capita which has led it towards being a major player in this industry globally.
Some Of The Growth Factors Of This Market:
- The increasing number of patients suffering from chronic heart failure and other cardiovascular disorders is also expected to fuel the demand for therapeutic proteins in this market over the next few years.
- In addition, technological advancements in drug discovery and development are also expected to drive growth in this market over the forecast period as they help develop more effective drugs with fewer side effects for treating various types of cardiovascular disorders such as hypertension, coronary artery disease (CAD), congestive heart failure (CHF), arrhythmia, myocardial infarction (MI) etc, which will lead to improved patient outcomes and increased life expectancy rates across all age groups worldwide.
Industry Growth Insights published a new data on “Therapeutic Proteins for Cardiovascular Disorders Treatment Market”. The research report is titled “Therapeutic Proteins for Cardiovascular Disorders Treatment Market research by Types (Monoclonal Antibodies Proteins, Peptides Proteins, Peptide Fragments Proteins), By Applications (Heart Failure, Myocardial Infarction, Arrhythmias, Coronary Artery Disease, Ischemic Heart Disease), By Players/Companies Johnson & Johnson, Eli Lilly & Company, Roche, Pfizer, Bristol Myers Squibb, Sanofi, Merck, Amgen, Novartis, Siemens Healthineers”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Therapeutic Proteins for Cardiovascular Disorders Treatment Market Research Report
By Type
Monoclonal Antibodies Proteins, Peptides Proteins, Peptide Fragments Proteins
By Application
Heart Failure, Myocardial Infarction, Arrhythmias, Coronary Artery Disease, Ischemic Heart Disease
By Companies
Johnson & Johnson, Eli Lilly & Company, Roche, Pfizer, Bristol Myers Squibb, Sanofi, Merck, Amgen, Novartis, Siemens Healthineers
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Report Segments:
The global Therapeutic Proteins for Cardiovascular Disorders Treatment market is segmented on the basis of:
Types
Monoclonal Antibodies Proteins, Peptides Proteins, Peptide Fragments Proteins
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Heart Failure, Myocardial Infarction, Arrhythmias, Coronary Artery Disease, Ischemic Heart Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Eli Lilly & Company
- Roche
- Pfizer
- Bristol Myers Squibb
- Sanofi
- Merck
- Amgen
- Novartis
- Siemens Healthineers
Highlights of The Therapeutic Proteins for Cardiovascular Disorders Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies Proteins
- Peptides Proteins
- Peptide Fragments Proteins
- By Application:
- Heart Failure
- Myocardial Infarction
- Arrhythmias
- Coronary Artery Disease
- Ischemic Heart Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Therapeutic Proteins for Cardiovascular Disorders Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Therapeutic proteins for cardiovascular disorders treatment are proteins that help to improve the function of the heart and blood vessels. These proteins can help to reduce inflammation, promote healing, and protect against damage caused by atherosclerosis or other diseases that affect the heart.
Some of the major companies in the therapeutic proteins for cardiovascular disorders treatment market are Johnson & Johnson, Eli Lilly & Company, Roche, Pfizer, Bristol Myers Squibb, Sanofi, Merck, Amgen, Novartis, Siemens Healthineers.
The therapeutic proteins for cardiovascular disorders treatment market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Therapeutic Proteins for Cardiovascular Disorders Treatment Market - Supply Chain
4.5. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Forecast
4.5.1. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Absolute $ Opportunity
5. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibodies Proteins
5.3.2. Peptides Proteins
5.3.3. Peptide Fragments Proteins
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Application
6.3.1. Heart Failure
6.3.2. Myocardial Infarction
6.3.3. Arrhythmias
6.3.4. Coronary Artery Disease
6.3.5. Ischemic Heart Disease
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Demand Share Forecast, 2019-2026
9. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Application
9.4.1. Heart Failure
9.4.2. Myocardial Infarction
9.4.3. Arrhythmias
9.4.4. Coronary Artery Disease
9.4.5. Ischemic Heart Disease
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibodies Proteins
9.7.2. Peptides Proteins
9.7.3. Peptide Fragments Proteins
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Demand Share Forecast, 2019-2026
10. Latin America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Application
10.4.1. Heart Failure
10.4.2. Myocardial Infarction
10.4.3. Arrhythmias
10.4.4. Coronary Artery Disease
10.4.5. Ischemic Heart Disease
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibodies Proteins
10.7.2. Peptides Proteins
10.7.3. Peptide Fragments Proteins
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Therapeutic Proteins for Cardiovascular Disorders Treatment Demand Share Forecast, 2019-2026
11. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Application
11.4.1. Heart Failure
11.4.2. Myocardial Infarction
11.4.3. Arrhythmias
11.4.4. Coronary Artery Disease
11.4.5. Ischemi Heart Disease
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibodies Proteins
11.7.2. Peptides Proteins
11.7.3. Peptide Fragments Proteins
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Demand Share, 2019-2026
12. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Application
12.4.1. Heart Failure
12.4.2. Myocardial Infarction
12.4.3. Arrhythmias
12.4.4. Coronary Artery Disease
12.4.5. Ischemic Heart Disease
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibodies Proteins
12.7.2. Peptides Proteins
12.7.3. Peptide Fragments Proteins
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Demand Share, 2019-2026
13. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Application
13.4.1. Heart Failure
13.4.2. Myocardial Infarction
13.4.3. Arrhythmias
13.4.4. Coronary Artery Disease
13.4.5. Ischemic Heart Disease
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibodies Proteins
13.7.2. Peptides Proteins
13.7.3. Peptide Fragments Proteins
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market: Market Share Analysis
14.2. Therapeutic Proteins for Cardiovascular Disorders Treatment Distributors and Customers
14.3. Therapeutic Proteins for Cardiovascular Disorders Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Johnson & Johnson
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly & Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bristol Myers Squibb
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Amgen
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novartis
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Siemens Healthineers
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
